Two new AI features for in-store analytics made possible by Xovis 3D sensors ZOLLIKOFEN, Switzerland, July 2, 2020 — When their ordinary "all-in-a-day’s-work" became extraordinary, Xovis ramped up their R&D to solve unforeseen challenges. Today, the company proudly presents two new AI features…
Clarivate Introduces Next Generation Insights Platform with Cortellis Generics Intelligence
Enhanced Newport platform allows for comprehensive and accurate analysis of market, API and patent data from a single application LONDON, July 1, 2020 — Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the launch of Cortellis Generics Intelligence™ to…
Sweeping Workplace Changes Expected in a Post-pandemic World, Says Research From The Adecco Group
Businesses and workers call for greater flexibility, questions raised over the hours-based contract, and a new empathetic leadership profile emerges ZURICH, June 30, 2020 — Workers demand greater flexibility after coronavirus, with a 50/50 split of remote and office time confirmed as…
PolyU collaborates with Macau University of Science and Technology to advance diagnosis of COVID-19 pneumonia
HONG KONG, June 15, 2020 /PRNewswire/ — COVID-19 is taking its toll on the world, affecting more than 200 countries and regions. In the face of a surge in cases, rapid diagnosis and identification of high-risk patients for early intervention is crucial for controlling the pandemic. The Hong Kong Polytechnic University (PolyU) is committed to the fight against COVID-19 and has been collaborating with various partners in the prevention and control of the disease. PolyU today announced the launch of a new AI system jointly developed with the Macau University of Science and Technology (M.U.S.T.) in conjunction with other Chinese institutions, to assist in the rapid diagnosis of COVID-19 pneumonia. This research was published in the prestigious international journal Cell, in a paper entitled "Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography" (link).
(From left) Dr Johnson LAU, Adjunct Professor of the Department of Applied Biology and Chemical Technology of PolyU; Prof. Manson FOK, Faculty of Medicine of Macau University of Science and Technology (M.U.S.T.); Prof. Alexander WAI, Deputy President and Provost of PolyU; and Prof. Kang ZHANG, Faculty of Medicine of M.U.S.T. introduce a new AI system for rapid and accurate diagnosis of COVID-19 pneumonia.
The novel AI-assisted diagnostic system, based on computed tomography (CT) chest imaging, can efficiently distinguish COVID-19 pneumonia from other viral pneumonia, and predict the severity level in 20 seconds, with an accuracy of up to 90% or above. It assists radiologists and physicians in performing a quick diagnosis, especially when the health system is overloaded.
According to Professor Kang ZHANG of the Faculty of Medicine of M.U.S.T. — the first author of the research paper, the research team used a large CT database of 3,777 patients to train and test the AI system to differentiate novel coronavirus pneumonia (NCP) from other common pneumonia and normal controls. This system is able to provide accurate clinical prognosis that can aid clinicians when considering appropriate early clinical management and appropriate resource allocation. It has been developed to assist global clinicians in combating COVID-19.
Dr Johnson LAU, Adjunct Professor of the Department of Applied Biology and Chemical Technology of PolyU, explained that the AI team uses deep learning, semantic segmentation and multiple neural network architectures to create an accurate AI diagnostic system comprising texture analysis, quantitative measurements and diagnosis classification. In addition, based on the international standard for related research on lung lesions, lung, liver damage and relevant clinical indicators, they have also developed a comprehensive rating system to project the emergence of pneumonia severe lesions accurately for the follow-up treatment.
The scientists from PolyU and M.U.S.T. have also collaborated on other projects, including the seroconversion study in SARS-CoV-2 (COVID-19) patients in China, which helped pave the way for further diagnostic and therapeutic development to treat SARS-CoV-2. The study "Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China" was also recently published in another prestigious scientific journal Nature Medicine (link).
"Leveraging PolyU’s strengths and our collaborations with different research partners, we are able to contribute to the well-being of humankind. During the outbreak, we have developed a rapid automated diagnostic system to detect COVID-19 and have conducted various scientific experiments related to the pandemic," said Professor Alexander WAI, Deputy President and Provost of PolyU. "Since the establishment of the biotechnology and translational medicine international collaborative platform in 2018, PolyU has been working closely with M.U.S.T. and other partners from the United States and the Greater Bay Area for high-impact research. Our long-term cooperation has paved the way for us to respond quickly, and to use our expertise to develop this new AI system for the diagnosis and prognosis of COVID-19."
Professor Manson FOK, Dean of the Faculty of Medicine of M.U.S.T., remarked that this AI system had been implemented in many hospitals in different countries. M.U.S.T. is collaborating with several prominent universities including Baylor University, University of Buffalo and Stanford University to serve the US populations. He believed this application could soon be adopted in Hong Kong, more regions of Mainland China and worldwide.
COVID-19 is a new and highly contagious virus with over 7 million people infected (as of June 10). Researchers from PolyU and M.U.S.T. with their supportive partners will continue their efforts in COVID-19 research to use scientific technologies to combat this pandemic through prevention, diagnosis, treatment and control.
Photo – https://photos.prnasia.com/prnh/20200615/2830759-1?lang=0
Related Links :
http://www.polyu.edu.hk/htm/
BioWorld Recognized for Excellence of Information & Intelligence to Biopharmaceutical Industry
News service from Clarivate wins plethora of awards at 41st Annual SIPAwards
LONDON and PHILADELPHIA, June 10, 2020 /PRNewswire/ — BioWorld™, a part of Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, has been recognized for excellence in publishing by the Specialized Information Publishers Association (SIPA). BioWorld, the daily news service for biopharmaceutical and medical technology industries, is the recipient of seven SIPAwards.
BioWorld delivers actionable information and intelligence on the most innovative therapeutics and medical technologies in development. The global team reports breaking news and provides key perspectives on hundreds of therapeutics and devices in development – the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes.
Lynn Yoffee, News Director, BioWorld said, "Every day, we help our readers cut through the noise of information overload. Now ― more than ever ― it is increasingly vital that we continue to provide our readers with unique, compelling and quality content that enables drug and med-tech developers to make more informed decisions."
SIPA hosts the annual SIPAwards competition to recognize excellence in editorial, marketing and product success. Now in its 41st year, the awards highlight the information and insights provided to niche audiences around the world. BioWorld is now the recipient of 63 SIPAwards dating back to 1998, including 15 awards for its daily news service. This year it was honored in the following categories:
Best Daily Publication
For high-impact daily information.
- First Place: BioWorld
- Third Place: BioWorld MedTech
Best New or Relaunched Website
For outstanding website design and maneuverability within a site.
- First Place: BioWorld and BioWorld MedTech for its entry, titled "Hello Future, Goodbye PDF,"
Best Series
For best series, based on writing, editing and design; the scope and detail of coverage in the stories; the timeliness or "exclusive" value.
- First Place: BioWorld and BioWorld MedTech – Transforming drug, med-tech R&D with AI
Best Infographic
For infographics that clearly and concisely present information, processes or data consistent with the subject matter, target industry and voice of the media outlet.
- First Place: BioWorld, Karen Carey – Biopharma stocks up 26% on average since debut with Karuna
Best Use of Data
For work in which data plays an essential role. The work may feature any of several forms and formats, (e.g., infographics, trend analyses, blogs, interactive tools, data-based investigation) to enhance its overall effectiveness.
- Third Place: BioWorld, Karen Carey ― Generic approvals up 28% amid drug pricing concerns
Best Interpretive or Analytical Reporting, Healthcare/Regulatory/Education
For excellent interpretive or analytical reporting covering the healthcare, regulatory and education sectors, with an analysis or explanation of a difficult topic or idea.
- Third Place: BioWorld MedTech, Stacy Lawrence ― Experimental treatment could free patients with advanced type 2 diabetes from daily insulin injections
About Clarivate
Clarivate™ is a global leader in providing trusted information and insights to accelerate the pace of innovation. We offer subscription and technology-based solutions coupled with deep domain expertise that cover the entire lifecycle of innovation – from foundational research and ideas to protection and commercialization. Today, we’re setting a trail-blazing course to help customers turn bold ideas into life-changing inventions. Our portfolio consists of some of the world’s most trusted information brands, including the Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor™ and Techstreet™. For more information, please visit clarivate.com.
icometrix launches its icompanion platform for people with multiple sclerosis
LEUVEN, Belgium and CHICAGO, June 2, 2020 /PRNewswire/ — icometrix, the world leader to extract clinically meaningful data from brain scans, is proud to have launched the icompanion platform and phone application for people with multiple sclerosis on World MS Day! icompanion is a medical device and is currently available in English, French, German, and Dutch.
To support people with multiple sclerosis, icompanion provides an easy and secure app to track symptoms, treatments, and physician visits. Users can also obtain educational information on the meaning and quality of their brain scans by uploading their MRI scans onto the platform. With this, icompanion provides a solution to log events that occur between neurologist visits, by means of day-to-day symptom-tracking and standardized questionnaires (patient-reported outcomes).
"As a neurologist, you see a patient only a couple of times a year and we know that a lot of valuable information is lost in-between," says Dr. Helmut Butzkeuven, neurologist at the Monash University in Melbourne, and director of MSBase, the largest global multiple sclerosis registry. "To make informed clinical and treatment decisions, it is important to have a complete picture of how a patient is doing," Dr. Butzkeuven continues. "Medical devices such as icompanion can greatly help in democratizing care, since today, patient care depends on where you live and who cares for you," Dr. Butzkeuven concludes.
"icompanion helps me keep track of my symptoms. Even if they seem insignificant, they are crucial in helping me communicate with my physician and prepare my visits. I think it’s great that by using icompanion, my data can also support researchers in their fight against multiple sclerosis. To win this battle we need everyone’s help, and together we are stronger," shares Roberto Paolella, living with MS for 15 years.
"Offering care based on data and objective measures is crucial to move towards more personalized and precise medicine for people with neurological disorders," says Wim Van Hecke, CEO of icometrix. "That is why we founded icometrix and developed the CE-labeled and FDA-cleared icobrain MR and CT brain measures, which are becoming standard of care. Through icompanion, the gap between doctor visits is bridged with clinically meaningful and validated data. The seamless availability of the icompanion data to the health care provider is very important in this context," Wim Van Hecke states.
About icometrix
icometrix is the world leader in software solutions to obtain clinically meaningful data from brain MR and CT scans for patients with neurological conditions such as multiple sclerosis, brain trauma, epilepsy, dementia, Alzheimer’s, Parkinson’s, etc. The fully automated icobrain software from icometrix is FDA cleared and CE labeled and leverages artificial intelligence to quantify disease-specific brain structures. Today, icometrix is internationally active in over 100 clinical practices. Alongside this, icometrix works with healthcare providers and pharmaceutical companies on the evaluation of drug trials for neurological diseases.
Please visit icompanion.ms for further information.
Contact
Wim Van Hecke, CEO
[email protected]
+32 484 92 73 00
Press Kit
https://tinyurl.com/ybm7tjzm
ActLight Signs an Agreement on Single Photon Sensitivity Technology With Leading Sensors Company
LAUSANNE, Switzerland, May 27, 2020 /PRNewswire/ — ActLight, the Swiss technology firm known for its best in class signal-to-noise ratio photodiodes, announced today that it has signed a service agreement based on its Single Photon Sensitivity technology with a leading company in the sensors market.
"Even though the terms of the agreement cannot be disclosed, we are very pleased that our innovative Single Photon Sensitivity technology attracted a leading player in the sensors field," said Maxim Gureev, Chief Technology Officer at ActLight. "The adoption of Single Photon Avalanche Diode (SPAD) array in 3D sensing chips is growing fast. The precision of 3D sensing in applications such as smartphones, cars and smart robotics will benefit from this collaboration with our customer and our talented team of engineers is already intensively working to make it happen."
About ActLight SA
ActLight SA, the start-up company founded in 2011 and based in Switzerland, focuses on the field of CMOS photonics by developing a new type of photodetector, the Dynamic PhotoDiode (DPD). Being a fabless company, ActLight specializes in the Intellectual Property (IP) of this area and operates primarily in the IP licensing business model.
The patented CMOS-based photonics technology allows the substantial improvement of the efficiency and accuracy of various light sensing applications, such as Time Of Flight (TOF) based range meters, vital signs monitoring, 3D/2D cameras and much more. ActLight operates in the Internet of Things (IoT) market, with a focus on mobile and wearable devices, healthcare/medtech, autonomous driving, drones and robotics.
More info about ActLight available at http://www.act-light.com
Contact:
[email protected]
Photo – https://techent.tv/wp-content/uploads/2020/05/actlight-signs-an-agreement-on-single-photon-sensitivity-technology-with-leading-sensors-company.jpg
Logo – https://techent.tv/wp-content/uploads/2020/05/actlight-signs-an-agreement-on-single-photon-sensitivity-technology-with-leading-sensors-company-1.jpg
Related Links :
http://www.act-light.com/
Glemser Technologies and Arria NLG announce strategic partnership
Together they will accelerate pharma clients’ ability to bring life-saving drugs to market through automation of medical and regulatory report writing NEW YORK, May 20, 2020 /PRNewswire/ — Arria NLG, a leading provider of Natural Language Generation (NLG) technology, today announced…
VeChain and I-Dante Partnered to Create Blockchain Enabled Medical Data Management Platform for Healthcare Provider in Cyprus
SHANGHAI, May 18, 2020 /PRNewswire/ — With more than 4.6 million infections, 300 thousand deaths and counting caused by COVID-19, national governments, healthcare systems regardless of region and continent have been scrambling to respond to it, and the pandemic has highlighted…
Telehealth to Experience Massive Growth with COVID-19 Pandemic, Says Frost & Sullivan
Demand for telehealth will soar by 64.3% in the US in 2020 as the COVID-19 pandemic disrupts the practice of medicine and the delivery of healthcare SANTA CLARA, California, May 14, 2020 /PRNewswire/ — Frost & Sullivan’s recent analysis, Telehealth—A Technology-Based…